Table of Contents
Chemotherapy Research and Practice
Volume 2015, Article ID 512016, 4 pages
Research Article

Oral Antineoplastic Agents: Assessing the Delay in Care

1Wake Forest Baptist Health, Medical Center Boulevard, Winston-Salem, NC 27157, USA
2West Virginia University Healthcare, 1 Medical Center Drive, Morgantown, WV 26506, USA
3Clinical Department, West Virginia University School of Pharmacy, Morgantown, WV 26506, USA

Received 29 May 2015; Accepted 5 October 2015

Academic Editor: Tadeusz Robak

Copyright © 2015 Brandi Anders et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The study was undertaken to determine the length of time between when a prescription for an oral antineoplastic agent is written by the provider and when the medication is received by the patient and to identify risk factors that significantly increase time to medication receipt. First-time fill prescriptions for oral antineoplastic agents were identified. The date the prescription was written and received by the patient was determined. A retrospective review was completed to gather additional information, including prescribed medication, indication, insurance coverage, patient assistance program use, dispensing pharmacy, and prior authorization requirements. The data was analyzed through multivariate statistical analysis and used to identify risk factors that may significantly increase the time to medication receipt. A total of 58 patients were included in the study. A median of 8 days elapsed between when the medication was prescribed and when it was received by the patient. Medication prescribed, absence of a Risk Evaluation Mitigation Strategies (REMS) program, and insurance type are factors that increased time to medication receipt. An understanding of the median time involved, as well as factors affecting the time to delivery of prescriptions, will help healthcare providers better plan and prepare for the use of oral antineoplastic agents.